CDBIO(SH:688739) Ge Long Hui·2026-02-12 11:13Core Viewpoint - The approval of a high-dose influenza virus split vaccine by Chengda Biological's subsidiary marks a significant step in addressing the growing demand for influenza prevention among the aging population in China [1][2] Group 1: Vaccine Approval and Characteristics - Chengda Biological's high-dose influenza virus split vaccine has received approval from the National Medical Products Administration to conduct clinical trials [1] - The vaccine is developed using WHO-recommended strains and has an antigen content four times that of standard-dose influenza vaccines, targeting individuals aged 60 and above [1] Group 2: Market Context and Implications - The aging population in China is increasing, leading to a heightened demand for effective influenza prevention strategies among the elderly [2] - Currently, there are no high-dose influenza vaccines approved for sale in China, making this clinical trial approval a crucial step for the company in responding to health aging strategies [2] Group 3: Future Development and Strategic Goals - Chengda Biological aims to continue its innovation-driven development strategy, enhancing its technological platform and the ability to translate research outcomes into products [2] - The company plans to advance the research and development of influenza vaccines and other key projects to improve public health and contribute to the high-quality development of China's biopharmaceutical industry [2]